Athersys Investor Relations Material
Latest events
Investor Update
Athersys
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Athersys Inc
Access all reports
Athersys, Inc., through its subsidiary, Healios K.K., focuses on the research and development of MultiStem cell therapy to treat various diseases; and marketing and developing of MultiStem as an off-the-shelf cell therapy to treat acute myocardial infarction, acute respiratory distress syndrome, ischemic stroke, and traumatic brain injury. It also focuses on research and development activities for a range of therapeutic applications in other areas, including hematology, inflammatory bowel disease and other gastrointestinal disorders, liver disease and repair, anti-inflammation in support of wound healing applications, bone fracture repair, trauma/surgical care applications, oncology supportive care applications, diabetes mellitus, retinitis pigmentosa, and human immunodeficiency virus associated morbidities.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ATHX
Country
🇺🇸 United States